Syrenity App for Depression

Not Applicable

Brief Summary: The goal of this clinical trial is to learn if the Syrenity mental health app reduces depressive symptoms when compared to a control condition. Secondarily, the trial will provide data on the usability and acceptability of the Syrenity app. The main questions it aims to answer are:

Does Syrenity reduce self-reported depressive symptoms compared to a waiting list control? How usable is the Syrenity app?

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Syrenity App	Syrenity App	The Syrenity App is a mental health app that has been designed to help improve mental health and well-being. The content on the app was created using cognitive-behavioral therapy principles. It uses both active and passive interventions. Active interventions are interventions where the user engages with the app in a back and forth dialogue (e.g., a conversation about restructuring unhelpful thoughts). Passive interventions meanwhile consist of text or videos that the user can read or watch and do not require dialogue with the app.

Primary Outcome Measures

Name	Time	Method
Patient Health Questionnaire 9 (PHQ-9)	6 weeks	Depression symptoms will be assessed with the PHQ-9. The PHQ-9 is a 9-item self-report measure that assesses the frequency of symptoms of major depressive disorder as outlined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Response options range from 0 ("not at all") to 3 (nearly every day). Total scores on the PHQ-9 range from 0-27 with greater scores indicating greater frequency of depressive symptoms. A score greater than or equal to 10 on the PHQ-9 has been identified as a positive screen for major depression (Kroenke \& Spitzer, 2002). PHQ-9 will be assessed at baseline, and each week of the intervention.

Secondary Outcome Measures

Name	Time	Method
Systems Usability Scale (SUS)	6 weeks	The SUS is a brief measure for assessing the usability of given systems (e.g., websites, mobile devices). The SUS has ten items and is rated on a five-point scale with responses ranging from zero ("strongly agree") to four ("strongly disagree"). Scale scores are multiplied by 2.5 to produce scores ranging from zero to 100 with higher scores indicating greater usability. We administered the SUS at the end of the intervention (week 6). However, investigators also administered a slightly modified version of the SUS at baseline to control for between-individual differences (e.g., the tendency to give high ratings). Participants were asked to rate their prediction of the usability of the book at baseline "based on the small amount of information \[they\] have on the study."
Generalized Anxiety Disorder Scale-7 (GAD-7)	6 weeks	Anxiety symptoms will be assessed with the GAD-7, a 7-item self-report measure that assesses the frequency of anxiety symptoms. Responses range from 0 ("not at all") to 3 ("nearly every day"), yielding total scores that range from 0-21 with greater scores indicating greater frequency of anxiety symptoms. A score greater than or equal to 10 on the GAD-7 has been identified as a positive screen for anxiety in primary care settings (Spitzer et al., 2006). GAD-7 will be assessed at baseline, and each week of the intervention.

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial